Literature DB >> 6694511

Reduced cholecystokinin immunoreactivity in the cerebrospinal fluid of patients with psychiatric disorders.

P M Verbanck, F Lotstra, C Gilles, P Linkowski, J Mendlewicz, J J Vanderhaeghen.   

Abstract

The close relationship of cholecystokinin peptides with some of the dopamine pathways and the limbic system suggests a putative role for these peptides in the pathophysiology of neuropsychiatric disorders such as Parkinson's disease, manic-depression and schizophrenia. By use of radioimmunoassay, we report a significant decrease in cholecystokinin-immunoreactivity in the cerebrospinal fluid of patients with bipolar manic-depression and untreated schizophrenia in comparison to control subjects.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6694511     DOI： 10.1016/0024-3205(84)90331-x

Source DB:  PubMed          Journal:  Life Sci        ISSN： 0024-3205            Impact factor:   5.037


  9 in total

1.  Neuronal cholecystokinin and schizophrenia: pathogenic and therapeutic studies.

Authors:  C A Tamminga; R L Littman; L D Alphs; T N Chase; G K Thaker; A M Wagman
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

Review 2.  Alterations in neuropeptides in aging and disease. Pathophysiology and potential for clinical intervention.

Authors:  A Leake; I N Ferrier
Journal:  Drugs Aging       Date:  1993 Sep-Oct       Impact factor: 3.923

3.  Cholecystokinin and tyrosine hydroxylase messenger RNAs in neurons of rat mesencephalon: peptide/monoamine coexistence studies using in situ hybridization combined with immunocytochemistry.

Authors:  K Seroogy; M Schalling; S Brené; A Dagerlind; S Y Chai; T Hökfelt; H Persson; M Brownstein; R Huan; J Dixon
Journal:  Exp Brain Res       Date:  1989       Impact factor: 1.972

4.  Characterization of [3H]cholecystokinin octapeptide binding to mouse brain synaptosomes: effects of neuroleptics.

Authors:  Y Hama; M Ebadi
Journal:  Neurochem Res       Date:  1987-08       Impact factor: 3.996

5.  Cholecystokinin and psychiatric disorders : role in aetiology and potential of receptor antagonists in therapy.

Authors:  J Shlik; E Vasar; J Bradwejn
Journal:  CNS Drugs       Date:  1997-08       Impact factor: 5.749

6.  Neuropeptides involved in the pathophysiology of schizophrenia and major depression.

Authors:  David De Wied; Hein O. Sigling
Journal:  Neurotox Res       Date:  2002 Aug-Sep       Impact factor: 3.911

7.  Cholecystokinin binding sites in the rat forebrain: effects of acute and chronic methamphetamine administration.

Authors:  T Suzuki; T Moroji
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

8.  Blockade of the cholecystokinin CCK-2 receptor prevents the normalization of anxiety levels in the rat.

Authors:  Santiago J Ballaz; Michel Bourin; Huda Akil; Stanley J Watson
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2019-09-14       Impact factor: 5.067

Review 9.  Diagnostic cerebrospinal fluid biomarkers for Parkinson's disease: a pathogenetically based approach.

Authors:  Karin D van Dijk; Charlotte E Teunissen; Benjamin Drukarch; Connie R Jimenez; Henk J Groenewegen; Henk W Berendse; Wilma D J van de Berg
Journal:  Neurobiol Dis       Date:  2010-05-06       Impact factor: 5.996
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.